4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Diabetic heart disease: A clinical update

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diabetes mellitus (DM) significantly increases the risk of heart disease, and DM-related healthcare expenditure is predominantly for the management of cardiovascular complications. Diabetic heart disease is a conglomeration of coronary artery disease (CAD), cardiac autonomic neuropathy (CAN), and diabetic cardiomyopathy (DCM). The Framingham study clearly showed a 2 to 4-fold excess risk of CAD in patients with DM. Pathogenic mechanisms, clinical presentation, and management options for DM-associated CAD are somewhat different from CAD among nondiabetics. Higher prevalence at a lower age and more aggressive disease in DM-associated CAD make diabetic individuals more vulnerable to premature death. Although common among diabetic individuals, CAN and DCM are often under-recognised and undiagnosed cardiac complications. Structural and functional alterations in the myocardial innervation related to uncontrolled diabetes result in damage to cardiac autonomic nerves, causing CAN. Similarly, damage to the cardiomyocytes from complex pathophysiological processes of uncontrolled DM results in DCM, a form of cardiomyopathy diagnosed in the absence of other causes for structural heart disease. Though optimal management of DM from early stages of the disease can reduce the risk of diabetic heart disease, it is often impractical in the real world due to many reasons. Therefore, it is imperative for every clinician involved in diabetes care to have a good understanding of the pathophysiology, clinical picture, diagnostic methods, and management of diabetes-related cardiac illness, to reduce morbidity and mortality among patients. This clinical review is to empower the global scientific fraternity with up-to-date knowledge on diabetic heart disease.

          Related collections

          Most cited references149

          • Record: found
          • Abstract: found
          • Article: not found

          Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

          The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

            The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

              The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
                Bookmark

                Author and article information

                Contributors
                Journal
                World J Diabetes
                WJD
                World Journal of Diabetes
                Baishideng Publishing Group Inc
                1948-9358
                15 April 2021
                15 April 2021
                : 12
                : 4
                : 383-406
                Affiliations
                College of Medical and Dental Sciences, University of Birmingham Medical School, Birmingham B15 2TH, United Kingdom
                Department of Endocrinology and Metabolism, Pilgrim Hospital, Boston PE21 9QS, United Kingdom
                Department of Endocrinology and Metabolism, Pilgrim Hospital, Boston PE21 9QS, United Kingdom
                Department of Medicine, The University of Manchester Medical School, Manchester M13 9PL, United Kingdom
                Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom
                Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom
                Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PL, United Kingdom. drpappachan@ 123456yahoo.co.in
                Author notes

                Author contributions: Rajbhandari J and Fernandez CJ performed majority of the initial drafting, prepared the figures and tables, and share the first authorship of the paper; Agarwal M and Yeap BXY did additional literature search and made critical revisions in the write up; Pappachan JM conceived the idea, made critical revisions and provided final approval of the final version of the manuscript to be published.

                Corresponding author: Joseph M Pappachan, FRCP, MD, Consultant Physician-Scientist, Honorary Research Fellow, Senior Researcher, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@ 123456yahoo.co.in

                Article
                jWJD.v12.i4.pg383
                10.4239/wjd.v12.i4.383
                8040078
                33889286
                f0b2e127-02c6-436f-b710-f8735f7f5d3c
                ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

                This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

                History
                : 25 January 2021
                : 27 February 2021
                : 13 March 2021
                Categories
                Review

                diabetic heart disease,type 2 diabetes mellitus,type 1 diabetes mellitus,coronary artery disease,cardiovascular disease,cardiac autonomic neuropathy,diabetic cardiomyopathy

                Comments

                Comment on this article